Completed PHASE3 INTERVENTIONAL NCT00035269

New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

Linezolid in the Treatment of Penicillin-Resistant Streptococcus Pneumoniae Pneumonia: An Open-Label, Non-Comparator Study

Sponsor: Pfizer

Conditions Community Acquired Infections Gram-positive Bacterial Infections Pneumonia, Pneumococcal

Interventions Antibiotic

Updated 6 times since 2017 Last updated: Apr 25, 2011 Started: Dec 31, 2001 Completion: May 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Community Acquired Infections and Gram-positive Bacterial Infections, this trial is completed. The trial is conducted by Pfizer and has accumulated 6 data snapshots since 2001. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Baltimore, United States , Barcelona, Spain , Baton Rouge, United States , Bratislava, Slovakia , Charlottesville, United States , Columbus, United States , Dallas, United States , Fleetwood, United States , Girona, Spain and 29 more locations